207_Combined course Presentations

Basket trials matching patients to therapies based on molecular profiles

Primary outcome measure(s)

Clinicaltrials. gov identifier

Program name

Lead organization

# Expected to accrue

Design Histology Indication

BRAFV600E mutation– positive tumor: including anaplastic thyroid cancer, biliary tract cancer, gastrointestinal stromal tumor Nonseminomato us germ cell tumor/nonsemin omatous germ cell tumor, hairy cell leukemia, WHO grade 1 or 2 glioma, WHO grade 3 or 4 (high-grade) glioma, multiple myeloma, and adenocarcinoma of the small intestine

Dabrafenib and trametinib in BRAFV600E- mutated rare cancers

Advanced disease without standard treatment options

GlaxoSmithKline NR

135

ORR

NCT02034110

Advanced disease without standard treatment options

ORR